Stages II-III Multiple Myeloma

Panobinostat Plus Velcade and Dexamethasone Shows Promise in Heavily Pretreated Myeloma (11-18-2013)

The experimental drug panobinostat (LBH-589) in combination with Velcade® (bortezomib) and dexamethasone is effective for heavily pretreated multiple myeloma, according to the final results from a phase 2 clinical trial published in Blood. Multiple myeloma... Continue Reading

Zevalin Effective in Relapsed/Refractory Follicular Lymphoma (01-11-2013)

Pomalidomide plus low-dose dexamethasone (LoDEX) significantly increased progression-free survival and overall survival compared with high-dose dexamethasone (HiDEX) in patients with refractory multiple myeloma, according to the results of a phase III... Continue Reading

Pomalidomide Improves Survival in Refractory Multiple Myeloma (01-8-2013)

Pomalidomide plus low-dose dexamethasone (LoDEX) significantly increased progression-free survival and overall survival compared with high-dose dexamethasone (HiDEX) in patients with refractory multiple myeloma, according to the results of a phase III... Continue Reading

MLN9708 “Oral Velcade” Shows Promise in Multiple Myeloma (01-3-2013)

The investigational, oral proteasome inhibitor MLN9708, which is a new version of Velcade® (bortezomib)—may be more effective and better tolerated than the Velcade injections, according to data from a mid-stage study presented at the 54th Annual Meeting... Continue Reading

Velcade Effective for Induction and Maintenance Treatment of Multiple Myeloma (09-7-2012)

Velcade® (bortezomib) during induction and maintenance treatment improves survival in newly diagnosed stage II or III multiple myeloma, according to the results of a study published in the Journal of Clinical Oncology. Multiple myeloma is a cancer of... Continue Reading

Three Studies Show Revlimid Provides Benefits—and Risks—in Multiple Myeloma (05-18-2012)

Maintenance therapy with Revlimid® (lenalidomide) has been shown to significantly improve progression-free survival and time to progression in multiple myeloma, according to the results of three studies published in the New England Journal of Medicine. Multiple... Continue Reading

Revlimid Increases Risk of Some New Cancers (05-15-2012)

Patients with newly diagnosed multiple myeloma who receive Revlimid® (lenalidomide) may be at an increased risk of developing new cancers, according to a safety announcement released by the U.S. Food and Drug Administration (FDA). Revlimid is an oral... Continue Reading

Carfilzomib Promising in Newly Diagnosed Multiple Myeloma (03-13-2012)

The investigational drug carfilzomib, in combination with Revlimid® (lenalidomide) and low-dose dexamethasone, produced high response rates in patients with newly diagnosed myeloma. The results of this Phase I/II clinical trial were presented at the... Continue Reading

Velcade Improves Survival with Multiple Myeloma (12-16-2011)

Final results from the VISTA trial demonstrate that the addition of Velcade® (bortezomib) to melphalan and prednisone substantially improves overall survival among patients with previously untreated multiple myeloma. These results were presented at the... Continue Reading

Mini-Transplants Continue to Show Promise for Older Patients with Multiple Myeloma (11-16-2011)

Less toxic cancer treatment followed by an allogeneic stem cell transplant is showing promise for older patients with advanced blood and bone marrow cancers such as multiple myeloma. These results were published in the Journal of the American Medical... Continue Reading

« Previous PageNext Page »